These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 14671731)

  • 1. Insight in obsessive compulsive disorder and body dysmorphic disorder.
    Eisen JL; Phillips KA; Coles ME; Rasmussen SA
    Compr Psychiatry; 2004; 45(1):10-5. PubMed ID: 14671731
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Delusionality and response to open-label fluvoxamine in body dysmorphic disorder.
    Phillips KA; McElroy SL; Dwight MM; Eisen JL; Rasmussen SA
    J Clin Psychiatry; 2001 Feb; 62(2):87-91. PubMed ID: 11247107
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Level of insight and clinical features of obsessive-compulsive disorder with and without body dysmorphic disorder.
    Nakata AC; Diniz JB; Torres AR; de Mathis MA; Fossaluza V; Bragancas CA; Ferrão Y; Miguel EC
    CNS Spectr; 2007 Apr; 12(4):295-303. PubMed ID: 17426667
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparison of insight in body dysmorphic disorder and obsessive-compulsive disorder.
    Phillips KA; Pinto A; Hart AS; Coles ME; Eisen JL; Menard W; Rasmussen SA
    J Psychiatr Res; 2012 Oct; 46(10):1293-9. PubMed ID: 22819678
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Obsessive-compulsive disorder versus body dysmorphic disorder: a comparison study of two possibly related disorders.
    Phillips KA; Pinto A; Menard W; Eisen JL; Mancebo M; Rasmussen SA
    Depress Anxiety; 2007; 24(6):399-409. PubMed ID: 17041935
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of fluvoxamine in body dysmorphic disorder.
    Phillips KA; Dwight MM; McElroy SL
    J Clin Psychiatry; 1998 Apr; 59(4):165-71. PubMed ID: 9590666
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacotherapy for body dysmorphic disorder: treatment received and illness severity.
    Phillips KA; Pagano ME; Menard W
    Ann Clin Psychiatry; 2006; 18(4):251-7. PubMed ID: 17162625
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Insight in body dysmorphic disorder with and without comorbid obsessive-compulsive disorder.
    Marazziti D; Giannotti D; Catena MC; Carlini M; Dell'Osso B; Presta S; Pfanner C; Mungai F; Dell'Osso L
    CNS Spectr; 2006 Jul; 11(7):494-8. PubMed ID: 16816788
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of factor-analyzed symptom dimensions to predict outcome with serotonin reuptake inhibitors and placebo in the treatment of obsessive-compulsive disorder.
    Mataix-Cols D; Rauch SL; Manzo PA; Jenike MA; Baer L
    Am J Psychiatry; 1999 Sep; 156(9):1409-16. PubMed ID: 10484953
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized placebo-controlled trial of fluoxetine in body dysmorphic disorder.
    Phillips KA; Albertini RS; Rasmussen SA
    Arch Gen Psychiatry; 2002 Apr; 59(4):381-8. PubMed ID: 11926939
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Obsessive-compulsive disorder and body dysmorphic disorder: a comparison of clinical features.
    Frare F; Perugi G; Ruffolo G; Toni C
    Eur Psychiatry; 2004 Aug; 19(5):292-8. PubMed ID: 15276662
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Brown Assessment of Beliefs Scale: reliability and validity.
    Eisen JL; Phillips KA; Baer L; Beer DA; Atala KD; Rasmussen SA
    Am J Psychiatry; 1998 Jan; 155(1):102-8. PubMed ID: 9433346
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Insight in body dysmorphic disorder (BDD) relative to obsessive-compulsive disorder (OCD) and psychotic disorders: Revisiting this issue in light of DSM-5.
    Toh WL; Castle DJ; Mountjoy RL; Buchanan B; Farhall J; Rossell SL
    Compr Psychiatry; 2017 Aug; 77():100-108. PubMed ID: 28651226
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Body dysmorphic disorder in the DSM-IV field trial for obsessive-compulsive disorder.
    Simeon D; Hollander E; Stein DJ; Cohen L; Aronowitz B
    Am J Psychiatry; 1995 Aug; 152(8):1207-9. PubMed ID: 7625473
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A retrospective review of clinical characteristics and treatment response in body dysmorphic disorder versus obsessive-compulsive disorder.
    Saxena S; Winograd A; Dunkin JJ; Maidment K; Rosen R; Vapnik T; Tarlow G; Bystritsky A
    J Clin Psychiatry; 2001 Jan; 62(1):67-72; quiz 73. PubMed ID: 11235937
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Body dysmorphic disorder: diagnostic controversies and treatment challenges.
    Phillips KA
    Bull Menninger Clin; 2000; 64(1):18-35. PubMed ID: 10695157
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Body dysmorphic disorder in patients with obsessive-compulsive disorder: prevalence and clinical correlates.
    Conceição Costa DL; Chagas Assunção M; Arzeno Ferrão Y; Archetti Conrado L; Hajaj Gonzalez C; Franklin Fontenelle L; Fossaluza V; Constantino Miguel E; Rodrigues Torres A; Gedanke Shavitt R
    Depress Anxiety; 2012 Nov; 29(11):966-75. PubMed ID: 22815241
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dimensional correlates of poor insight in obsessive-compulsive disorder.
    Jakubovski E; Pittenger C; Torres AR; Fontenelle LF; do Rosario MC; Ferrão YA; de Mathis MA; Miguel EC; Bloch MH
    Prog Neuropsychopharmacol Biol Psychiatry; 2011 Aug; 35(7):1677-81. PubMed ID: 21640153
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dimensional predictors of response to SRI pharmacotherapy in obsessive-compulsive disorder.
    Landeros-Weisenberger A; Bloch MH; Kelmendi B; Wegner R; Nudel J; Dombrowski P; Pittenger C; Krystal JH; Goodman WK; Leckman JF; Coric V
    J Affect Disord; 2010 Feb; 121(1-2):175-9. PubMed ID: 19577308
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current concepts in body dysmorphic disorder.
    Carroll DH; Scahill L; Phillips KA
    Arch Psychiatr Nurs; 2002 Apr; 16(2):72-9. PubMed ID: 11925574
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.